SCHEMBL3602186

SCHEMBL3602186

Cc1ccc2c(c1)ncn2CC(=O)NCCN(C)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.41
MAPT P10636 3/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
CDK5 Q00535 1/20 0.41
TRPA1 O75762 1/20 0.41
HPGD P15428 3/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CASP1 P29466 1/20 0.40
P2RY12 Q9H244 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599700 0.93 ATM (0.42) TP53MAPTCCNE1CDK2CDK5
SCHEMBL5345349 0.92 TRPA1 (0.43) TP53MAPTCCNE1CDK2CDK5
SCHEMBL3597098 0.89 KMT2A (0.42) TP53MAPTCCNE1CDK2CDK5
SCHEMBL3606205 0.88 TP53 (0.45) TP53MAPTHPGDMEN1KMT2A
SCHEMBL13115590 0.87 ATM (0.47)
SCHEMBL3605821 0.85 CCNE1 (0.43) TP53MAPTCCNE1CDK2CDK5
SCHEMBL13115367 0.83 TRPA1 (0.42) TP53MAPTCCNE1CDK2CDK5
SCHEMBL3602189 0.82 HPGD (0.43) TP53MAPTCCNE1CDK2CDK5
SCHEMBL5367265 0.82 MTNR1A (0.52) TP53MAPTP2RY12ALDH1A1
SCHEMBL14396668 0.81 GAA (0.43) TP53MAPTTRPA1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 TP53 1777/4885MAPT 2809/4885CCNE1 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.